UK-CAB 17 – Cancer and HIV – Gilead

26 May 2006

Programme

09:30 – 10.00 Registration and coffee
10.00 – 11.15 i) Conference feedback and news / issues report ii) BHIVA Community Dinner

iii) EATG

iv) NAM meeting – New Developments in Treatment

v) Issues discussion Interface with BHIVA Message board issues to be presented and discussed

vi) Gilead pre-meeting

11:15 – 11:30 Break
11:30 –13.00 Company meeting: Gilead
13:00 –14:00 Lunch
14.30 – 15:30 Cancer and HIV – Mark Bower, Oncologist at the Chelsea and Westminster and St Mary’s
15:30 – 16.00 Future steering group – There is a fuller discussion about the future steering group and the need to have a process for opening this out.

 

Financial support

The UK-CAB receives unrestricted funding from some pharmaceutical companies towards the direct costs of holding four meetings each year. This funding supports the travel and accommodation costs for members to attend from outside London, plus the cost of catering.

The content, programme and agenda for meetings is decided by the UK-CAB steering group in consultation with the wider membership. Funding is unconnected to meeting content.

We believe that manufacturers who currently develop and market medicines have a responsibility to actively engage with advocacy organisations and that HIV positive people and their advocates should be able to directly question manufacturers about the safety and efficacy of their products and proposals for future research.

For a list of companies that support the UK-CAB please see the “about us” page.

Edit
Published: May 26, 2006
Last edited: August 14, 2013